Treatment of stimulant use disorder: A systematic review of reviews.
Claire Ronsley,Seonaid Nolan,Rod Knight,Kanna Hayashi,Jano Klimas,Alexander Y. Walley,Alexander Y. Walley,Evan Wood,Nadia Fairbairn +8 more
Reads0
Chats0
TLDR
There was sufficient evidence to support the efficacy of contingency management programs for treatment of stimulant use disorder, but psychostimulants, n-acetylcysteine, opioid agonist therapy, disulfiram and antidepressant pharmacological interventions were found to have insufficient evidence tosupport or discount their use.Abstract:
Aims Stimulant use disorder contributes to a substantial worldwide burden of disease, although evidence-based treatment options are limited This systematic review of reviews aims to: (i) synthesize the available evidence on both psychosocial and pharmacological interventions for the treatment of stimulant use disorder; (ii) identify the most effective therapies to guide clinical practice, and (iii) highlight gaps for future study Methods A systematic database search was conducted to identify systematic reviews and meta-analyses Eligible studies were those that followed standard systematic review methodology and assessed randomized controlled trials focused on the efficacy of interventions for stimulant use disorder Articles were critically appraised using an assessment tool adapted from Palmeteer et al and categorized for quality as ‘core’ or ‘supplementary’ reviews Evidence from the included reviews were further synthesized according to pharmacological or non-pharmacological management themes Results Of 476 identified records, 29 systematic reviews examining eleven intervention modalities were included The interventions identified include: contingency management, cognitive behavioural therapy, acupuncture, antidepressants, dopamine agonists, antipsychotics, anticonvulsants, disulfiram, opioid agonists, N-Acetylcysteine, and psychostimulants There was sufficient evidence to support the efficacy of contingency management programs for treatment of stimulant use disorder Psychostimulants, n-acetylcysteine, opioid agonist therapy, disulfiram and antidepressant pharmacological interventions were found to have insufficient evidence to support or discount their use Results of this review do not support the use of all other treatment options Conclusions The results of this review supports the use of contingency management interventions for the treatment of stimulant use disorder Although evidence to date is insufficient to support the clinical use of psychostimulants, our results demonstrate potential for future research in this area Given the urgent need for effective pharmacological treatments for stimulant use disorder, high-quality primary research focused on the role of psychostimulant medications for the treatment of stimulant use disorder is neededread more
Citations
More filters
Journal ArticleDOI
Vital Signs: Characteristics of Drug Overdose Deaths Involving Opioids and Stimulants — 24 States and the District of Columbia, January–June 2019
TL;DR: Identifying opportunities to intervene before an overdose death and implementing evidence-based prevention policies, programs, and practices could save lives, and strategies should address characteristics of overdoses involving IMFs, such as rapid overdose progression, as well as opioid and stimulant co-involvement.
Journal ArticleDOI
OUP accepted manuscript
TL;DR: In this paper , the authors used death certificate data from the US National Center for Health Statistics (2007-2019) to compare state-level trends in overdose mortality due to opioids in combination with 1) cocaine and 2) methamphetamine and other stimulants (MOS) across racial/ethnic groups (non-Hispanic White, non-Hispanic Black, Hispanic, and non- Hispanic Asian American/Pacific Islander).
Journal ArticleDOI
Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer?
TL;DR: Evaluating refined metrics of treatment success in well-defined subgroups of patients, and further exploring combination therapies and their synergy with behavioural/psychosocial interventions, are promising avenues to establishing effective therapies for CUD.
Journal ArticleDOI
Racial/Ethnic and Geographic Trends in Combined Stimulant/Opioid Overdoses, 2007-2019.
Tarlise Townsend,David Em Kline,Ariadne Rivera-Aguirre,Amanda M. Bunting,Pia M. Mauro,Brandon D.L. Marshall,Silvia S. Martins,Magdalena Cerdá +7 more
TL;DR: Compared state-level trends in overdose mortality due to opioids in combination with 1) cocaine and 2) methamphetamine and other stimulants across racial/ethnic groups (non-Hispanic White, non- Hispanic Black, Hispanic, and non-Hispanic Asian American/Pacific Islander) are used to compare.
Journal ArticleDOI
Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction.
Christopher M. Jones,Debra Houry,Beth Han,Grant T. Baldwin,Alana M. Vivolo-Kantor,Wilson M. Compton +5 more
TL;DR: In this paper, a narrative review synthesizes what is known about changing patterns of methamphetamine use with and without opioids in the United States, other characteristics associated with methamphetamine use, the contributions of the changing illicit drug supply to use patterns and overdose risk, motivations for couse of methamphetamine and opioids, and awareness of exposure to opioids via the illicit methamphetamine supply.
References
More filters
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
TL;DR: Moher et al. as mentioned in this paper introduce PRISMA, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses, which is used in this paper.
Journal Article
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
TL;DR: The QUOROM Statement (QUality Of Reporting Of Meta-analyses) as mentioned in this paper was developed to address the suboptimal reporting of systematic reviews and meta-analysis of randomized controlled trials.
Journal Article
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement [in Spanish]
David Moher,Alessandro Liberati,Jennifer Tetzlaff,Douglas G. Altman,Gerd Antes,David C. Atkins,Virginia Barbour,N Barrowman,Jesse A. Berlin,J Clark,Mike Clarke,Deborah J. Cook,Roberto D'Amico,Jonathan J Deeks,Philip J. Devereaux,Kay Dickersin,M Egger,E Ernst,P C Gøtzsche,Jeremy M. Grimshaw,G Guyatt,Julian P T Higgins,Ioannidis Jpa.,Jos Kleijnen,Tom Lang,N Magrini,D McNamee,Lorenzo Moja,C Mulrow,M Napoli,Andrew D Oxman,B Pham,Drummond Rennie,Margaret Sampson,Kenneth F. Schulz,Paul G. Shekelle,David Tovey,Peter Tugwell +37 more
Journal ArticleDOI
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
TL;DR: Methadone is an effective maintenance therapy intervention for the treatment of heroin dependence as it retains patients in treatment and decreases heroin use better than treatments that do not utilise opioid replacement therapy, and does not show a statistically significant superior effect on criminal activity.